LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 284

Search options

  1. Article ; Online: Peripheral photocoagulation not the answer for DMO.

    Campochiaro, Peter A

    Eye (London, England)

    2023  Volume 37, Issue 16, Page(s) 3302–3303

    MeSH term(s) Humans ; Ranibizumab ; Bevacizumab ; Light Coagulation ; Diabetic Retinopathy/surgery
    Chemical Substances Ranibizumab (ZL1R02VT79) ; Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2023-06-05
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 91001-6
    ISSN 1476-5454 ; 0950-222X
    ISSN (online) 1476-5454
    ISSN 0950-222X
    DOI 10.1038/s41433-023-02596-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3010: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 603: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Anti-VEGF

    Campochiaro, Peter A.

    3 tables

    (Ophthalmologica ; 227, Suppl. 1)

    2012  

    Author's details guest ed. Peter A. Campochiaro
    Series title Ophthalmologica ; 227, Suppl. 1
    Collection
    Language English
    Size 35 S. : Ill.
    Publisher Karger
    Publishing place Basel u.a.
    Publishing country Germany
    Document type Book
    HBZ-ID HT017227633
    ISBN 978-3-318-02151-6 ; 9783318021523 ; 3-318-02151-2 ; 3318021520
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ul I Zs 65 -227,Suppl.1- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture.

    Campochiaro, Peter A

    Investigative ophthalmology & visual science

    2021  Volume 62, Issue 14, Page(s) 26

    MeSH term(s) Animals ; Awards and Prizes ; Choroidal Neovascularization/epidemiology ; Forecasting ; History, 21st Century ; Humans ; Ophthalmology/history ; Societies, Medical/history ; United States ; Wet Macular Degeneration/epidemiology
    Language English
    Publishing date 2021-12-13
    Publishing country United States
    Document type Historical Article ; Journal Article
    ZDB-ID 391794-0
    ISSN 1552-5783 ; 0146-0404
    ISSN (online) 1552-5783
    ISSN 0146-0404
    DOI 10.1167/iovs.62.14.26
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 45: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Low risk to retina from sustained suppression of VEGF.

    Campochiaro, Peter A

    The Journal of clinical investigation

    2019  Volume 129, Issue 8, Page(s) 3029–3031

    MeSH term(s) Angiogenesis Inhibitors/therapeutic use ; Animals ; Humans ; Mice ; Retinal Diseases/drug therapy ; Retinal Diseases/metabolism ; Retinal Diseases/pathology ; Retinal Pigment Epithelium/metabolism ; Retinal Pigment Epithelium/pathology ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/biosynthesis
    Chemical Substances Angiogenesis Inhibitors ; VEGFA protein, human ; Vascular Endothelial Growth Factor A
    Language English
    Publishing date 2019-06-24
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI129861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab.

    Bhisitkul, Robert B / Campochiaro, Peter A / Blotner, Steven / Quezada-Ruiz, Carlos / Liu, Mimi / Haskova, Zdenka

    The British journal of ophthalmology

    2024  

    Abstract: Background/aims: We characterised the relationships between monitoring frequency, ranibizumab injection need and vision in patients receiving as-needed (pro re nata; PRN) ranibizumab for macular oedema due to branch retinal vein occlusion (BRVO) or ... ...

    Abstract Background/aims: We characterised the relationships between monitoring frequency, ranibizumab injection need and vision in patients receiving as-needed (pro re nata; PRN) ranibizumab for macular oedema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in this post-hoc analysis of SHORE and HORIZON.
    Methods: Patients aged 18 years and older with macular oedema due to BRVO/CRVO were included in this analysis. Injection frequency and best-corrected visual acuity (BCVA) were evaluated by PRN injection frequency in the PRN dosing phase (months (M) 7-15) of SHORE and through 12 months of HORIZON. Prespecified PRN re-treatment criteria for each trial were based on protocol-prespecified BCVA and optical coherence tomography outcomes.
    Results: After the initial 7 monthly ranibizumab injections, patients in SHORE gained a mean of 18.3 letters from baseline. Patients randomised to PRN, on average, maintained these gains. However, some patients experienced additional mean gains, whereas others suffered losses (range 4.0 (95% CI 0.7 to 7.3) to -4.6 (95% CI -11.8 to 2.6) letters in patients who received 0 and 6-7 PRN injections, respectively). In BRAVO and CRUISE (lead-in trials), patients experienced mean gains from baseline to M6 (monthly dosing) of 19.3 and 15.0 letters, respectively, with gains maintained with PRN from M6 to M12. However, mean BCVA changes from baseline to M12 varied in HORIZON (range -0.4 (95% CI -2.5 to 1.6) to -3.6 (95% CI -6.2 to -1.0) letters in patients who received zero and six injections, respectively, during the preceding PRN phase of BRAVO and CRUISE).
    Conclusion: The BRVO/CRVO population is heterogenous with a varied response to ranibizumab treatment.
    Language English
    Publishing date 2024-01-30
    Publishing country England
    Document type Journal Article
    ZDB-ID 80078-8
    ISSN 1468-2079 ; 0007-1161
    ISSN (online) 1468-2079
    ISSN 0007-1161
    DOI 10.1136/bjo-2022-323120
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ul I Zs.83: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye.

    Koh, Gou Young / Augustin, Hellmut G / Campochiaro, Peter A

    Trends in molecular medicine

    2022  Volume 28, Issue 5, Page(s) 347–349

    Abstract: ... into therapies, while Campochiaro evaluates their impact and value for clinical practice. ...

    Abstract Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
    MeSH term(s) Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Angiopoietin-2/therapeutic use ; Diabetic Retinopathy/drug therapy ; Humans ; Macular Edema/drug therapy ; Vascular Endothelial Growth Factor A
    Chemical Substances Angiogenesis Inhibitors ; Angiopoietin-2 ; Vascular Endothelial Growth Factor A
    Language English
    Publishing date 2022-04-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 2036490-8
    ISSN 1471-499X ; 1471-4914
    ISSN (online) 1471-499X
    ISSN 1471-4914
    DOI 10.1016/j.molmed.2022.03.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4345: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Comment on "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases".

    Campochiaro, Peter A / Barteselli, Giulio

    Eye (London, England)

    2020  Volume 35, Issue 3, Page(s) 1024–1025

    MeSH term(s) Bevacizumab ; Biocompatible Materials ; Humans ; Retinal Diseases
    Chemical Substances Biocompatible Materials ; Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2020-05-28
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 91001-6
    ISSN 1476-5454 ; 0950-222X
    ISSN (online) 1476-5454
    ISSN 0950-222X
    DOI 10.1038/s41433-020-0982-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3010: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 603: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases.

    Campochiaro, Peter A / Akhlaq, Anam

    Progress in retinal and eye research

    2020  Volume 83, Page(s) 100921

    Abstract: Neovascular age-related macular degeneration (NVAMD) is the most prevalent choroidal vascular disease, and diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the most prevalent retinal vascular diseases. In each of these, hypoxia plays a ... ...

    Abstract Neovascular age-related macular degeneration (NVAMD) is the most prevalent choroidal vascular disease, and diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the most prevalent retinal vascular diseases. In each of these, hypoxia plays a central role by stabilizing hypoxia-inducible factor-1 which increases production of vascular endothelial growth factor (VEGF) and other hypoxia-regulated gene products. High VEGF causes excessive vascular permeability, neovascularization, and in DR and RVO, promotes closure of retinal vessels exacerbating hypoxia and creating a positive feedback loop. Hence once VEGF expression is elevated it tends to remain elevated and drives disease progression. While other hypoxia-regulated gene products also contribute to pathology in these disease processes, it is remarkable how much pathology is reversed by selective inhibition of VEGF. Clinical trials have demonstrated outstanding visual outcomes in patients with NVAMD, DR, or RVO from frequent intraocular injections of VEGF-neutralizing proteins, but for a variety of reasons injection frequency has been substantially less in clinical practice and visual outcomes are disappointing. Herein we discuss the rationale, preclinical, and early clinical results of new approaches that provide sustained suppression of VEGF. These approaches will revolutionize the management of these prevalent retinal/choroidal vascular diseases.
    MeSH term(s) Diabetic Retinopathy ; Humans ; Retinal Diseases/drug therapy ; Retinal Vein Occlusion ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors
    Chemical Substances Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors
    Language English
    Publishing date 2020-11-25
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1182683-6
    ISSN 1873-1635 ; 1350-9462
    ISSN (online) 1873-1635
    ISSN 1350-9462
    DOI 10.1016/j.preteyeres.2020.100921
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 824: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Reduced inspired oxygen decreases retinal superoxide radicals and promotes cone function and survival in a model of retinitis pigmentosa.

    Kanan, Yogita / Hackett, Sean F / Hsueh, Henry T / Khan, Mahmood / Ensign, Laura M / Campochiaro, Peter A

    Free radical biology & medicine

    2023  Volume 198, Page(s) 118–122

    Abstract: Retinitis pigmentosa (RP) is caused by many different mutations that promote the degeneration of rod photoreceptors and have no direct effect on cones. After the majority of rods have died cone photoreceptors begin to slowly degenerate. Oxidative damage ... ...

    Abstract Retinitis pigmentosa (RP) is caused by many different mutations that promote the degeneration of rod photoreceptors and have no direct effect on cones. After the majority of rods have died cone photoreceptors begin to slowly degenerate. Oxidative damage contributes to cone cell death and it has been hypothesized that tissue hyperoxia due to reduced oxygen consumption from the loss of rods is what initiates oxidative stress. Herein, we demonstrate in animal models of RP that reduction of retinal hyperoxia by reducing inspired oxygen to continuous breathing of 11% O
    MeSH term(s) Animals ; Superoxides/metabolism ; Oxygen/metabolism ; Hyperoxia/metabolism ; Retina/metabolism ; Retinitis Pigmentosa/genetics ; Retinal Cone Photoreceptor Cells/metabolism ; Disease Models, Animal
    Chemical Substances Superoxides (11062-77-4) ; Oxygen (S88TT14065)
    Language English
    Publishing date 2023-02-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 807032-5
    ISSN 1873-4596 ; 0891-5849
    ISSN (online) 1873-4596
    ISSN 0891-5849
    DOI 10.1016/j.freeradbiomed.2023.01.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2109: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Molecular pathogenesis of retinal and choroidal vascular diseases.

    Campochiaro, Peter A

    Progress in retinal and eye research

    2015  Volume 49, Page(s) 67–81

    Abstract: There are two major types of ocular neovascularization that affect the retina, retinal neovascularization (NV) and subretinal or choroidal NV. Retinal NV occurs in a group of diseases referred to as ischemic retinopathies in which damage to retinal ... ...

    Abstract There are two major types of ocular neovascularization that affect the retina, retinal neovascularization (NV) and subretinal or choroidal NV. Retinal NV occurs in a group of diseases referred to as ischemic retinopathies in which damage to retinal vessels results in retinal ischemia. Most prevalent of these are diabetic retinopathy and retinal vein occlusions. Subretinal and choroidal NV occur in diseases of the outer retina and Bruch's membrane, the most prevalent of which is age-related macular degeneration. Numerous studies in mouse models have helped to elucidate the molecular pathogenesis underlying retinal, subretinal, and choroidal NV. There is considerable overlap because the precipitating event in each is stabilization of hypoxia inducible factor-1 (HIF-1) which leads to upregulation of several hypoxia-regulated gene products, including vascular endothelial growth factor (VEGF), angiopoietin 2, vascular endothelial-protein tyrosine phosphatase (VE-PTP), and several others. Stimulation of VEGF signaling and suppression of Tie2 by angiopoietin 2 and VE-PTP are critical for sprouting of retinal, subretinal, and choroidal NV, with perturbation of Bruch's membrane also needed for the latter. Additional HIF-1-regulated gene products cause further stimulation of the NV. It is difficult to model macular edema in animals and therefore proof-of-concept clinical trials were done and demonstrated that VEGF plays a central role and that suppression of Tie2 is also important. Neutralization of VEGF is currently the first line therapy for all of the above disease processes, but new treatments directed at some of the other molecular targets, particularly stabilization of Tie2, are likely to provide additional benefit for subretinal/choroidal NV and macular edema. In addition, the chronicity of these diseases as well as the implication of VEGF as a cause of retinal nonperfusion and progression of background diabetic retinopathy make sustained delivery approaches for VEGF antagonists a priority.
    MeSH term(s) Angiogenesis Inhibitors/therapeutic use ; Angiopoietin-2/metabolism ; Animals ; Choroid Diseases/drug therapy ; Choroid Diseases/etiology ; Choroid Diseases/metabolism ; Disease Models, Animal ; Humans ; Hypoxia-Inducible Factor 1/metabolism ; Intercellular Signaling Peptides and Proteins/metabolism ; Mice ; Neovascularization, Pathologic/etiology ; Neovascularization, Pathologic/metabolism ; Retinal Diseases/drug therapy ; Retinal Diseases/etiology ; Retinal Diseases/metabolism ; Vascular Endothelial Growth Factor A/metabolism
    Chemical Substances Angiogenesis Inhibitors ; Angiopoietin-2 ; Hypoxia-Inducible Factor 1 ; Intercellular Signaling Peptides and Proteins ; Vascular Endothelial Growth Factor A
    Language English
    Publishing date 2015-11
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1182683-6
    ISSN 1873-1635 ; 1350-9462
    ISSN (online) 1873-1635
    ISSN 1350-9462
    DOI 10.1016/j.preteyeres.2015.06.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 824: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top